Abstract: Pharmacogenomic (PGx) testing provides valuable insight into patient-specific mechanisms for drug response. Limitations on the throughput of PGx testing and associated costs make it currently infeasible to test every individual. It is with this in mind that we developed the Meaningful, Actionable Pharmacogenomic Patient Results (MAPPeR) tool in order to prioritize patients for PGx testing based on which are identified to most likely benefit from the testing.

Describe the new knowledge and additional skills the participant will gain after attending your presentation.: After this session, attendees should have an understanding of the importance of pharmacogenomic (PGx) testing and the implications of preemptive testing for a targeted set of patients using our developed method.

Authors:

Adam McDermaid (Presenter)
Sanford Health

April Schultz, Sanford Health
Catherine Hajek, Sanford Health
Murat Sincan, Sanford Health